IO biotech
Clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer.
Launch date
Employees
Market cap
€45.1m
Enterprise valuation
(€45m) (Public information from Sep 2024)
Share price
$1.19 IOBT
Company register number 36474483
Copenhagen Capital Region of Denmark (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 1.4m | 28.1m |
| % growth | - | - | - | - | - | - | 1962 % |
| EBITDA | (11.0m) | (61.6m) | (63.6m) | (77.1m) | (87.1m) | (111m) | (151m) |
| % EBITDA margin | - | - | - | - | - | (8120 %) | (537 %) |
| Profit | (10.9m) | (61.7m) | (65.0m) | (78.3m) | (79.9m) | (105m) | (117m) |
| % profit margin | - | - | - | - | - | (7667 %) | (417 %) |
| EV / revenue | - | - | - | - | - | -111.7x | -0.1x |
| EV / EBITDA | - | 0.4x | 1.1x | 0.2x | -0.6x | 1.4x | 0.0x |
| R&D budget | 7.7m | 27.4m | 42.7m | 61.7m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€11.0m | Series A | ||
DKK60.0m | Debt | ||
€127m | Series B | ||
| N/A | $100m Valuation: $388m -32.0x EV/LTM EBITDA | IPO | |
* | $75.0m | Private Placement VC | |
| Total Funding | €206m | ||
Related Content
Recent News about IO biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.